Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 5, 2011, Pages 532-537

  Kansaku, Fumiyasu ^a   Kumai, Toshio ^b   Sasaki, Kuniharu ^a   Yokozuka, Makito ^b   Shimizu, Makiko ^a   Tateda, Tadashi ^b   Murayama, Norie ^a   Kobayashi, Shinichi ^b   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Awakening time; P450 2B6; Risk index; UDP glucuronosyltransferase 1A9

Indexed keywords

PROPOFOL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CYP2B6 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; UGT1A9 GENE;

EID: 80055078449     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-039     Document Type: Article

References (19)

1. Bryson, H. M., Fulton, B. R. and Faulds, D.: Propofol. An update of its use in anaesthesia and conscious sedation. Drugs, 50: 513-559 (1995).
2. Mandsager, R. E., Clarke, C. R., Shawley, R. V. and Hague, C. M.: Effects of chloramphenicol on infusion pharmacokinetics of propofol in greyhounds. Am. J. Vet. Res., 56: 95-99 (1995).
3. Bray, R. J.: Propofol infusion syndrome in children. Paediatr. Anaesth., 8: 491-499 (1998).
4. 14C-propofol after intravenous dosing to rat, dog and rabbit. Xenobiotica, 21: 1243-1256 (1991).
5. Sneyd, J. R., Simons, P. J. and Wright, B.: Use of proton NMR spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient. Xenobiotica, 24: 1021-1028 (1994).
6. Girard, H., Villeneuve, L., Court, M. H., Fortier, L. C., Caron, P., Hao, Q., von Moltke, L. L., Greenblatt, D. J. and Guillemette, C.: The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos., 34: 1220-1228 (2006).
7. Murayama, N., Minoshima, M., Shimizu, M., Guengerich, F. P. and Yamazaki, H.: Involvement of human cytochrome P450 2B6 in the ω-and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica, 37: 717-724 (2007).
8. Guitton, J., Buronfosse, T., Desage, M., Flinois, J. P., Perdrix, J. P., Brazier, J. L. and Beaune, P.: Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br. J. Anaesth., 80: 788-795 (1998).
9. McKillop, D., Wild, M. J., Butters, C. J. and Simcock, C.: Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica, 28: 845-853 (1998).
10. Tanaka, E., Takano, Y., Inomata, S., Toyooka, H. and Honda, K.: Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro. Eur. J. Clin. Pharmacol., 60: 565-568 (2004).
11. Hamaoka, N., Oda, Y., Hase, I., Mizutani, K., Nakamoto, T., Ishizaki, T. and Asada, A.: Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study. Clin. Pharmacol. Ther., 66: 110-117 (1999).
12. Court, M. H., Duan, S. X., Hesse, L. M., Venkatakrishnan, K. and Greenblatt, D. J.: Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology, 94: 110-119 (2001).
13. Oda, Y., Hamaoka, N., Hiroi, T., Imaoka, S., Hase, I., Tanaka, K., Funae, Y. and Asada, A.: Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br. J. Clin. Pharmacol., 51: 281-285 (2001).
14. Favetta, P., Degoute, C. S., Perdrix, J. P., Dufresne, C., Boulieu, R. and Guitton, J.: Propofol metabolites in man following propofol induction and maintenance. Br. J. Anaesth., 88: 653-658 (2002).
15. Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics, 11: 399-415 (2001).
16. Saeki, M., Saito, Y., Jinno, H., Sai, K., Ozawa, S., Kurose, K., Kaniwa, N., Komamura, K., Kotake, T., Morishita, H., Kamakura, S., Kitakaze, M., Tomoike, H., Shirao, K., Tamura, T., Yamamoto, N., Kunitoh, H., Hamaguchi, T., Yoshida, T., Kubota, K., Ohtsu, A., Muto, M., Minami, H., Saijo, N., Kamatani, N. and Sawada, J. I.: Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J., 6: 63-75 (2006).
17. Yamazaki, H., Shimizu, M., Nagashima, T., Minoshima, M. and Murayama, N.: Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metab. Dispos., 34: 1803-1805 (2006).
18. Tsuchiya, K., Gatanaga, H., Tachikawa, N., Teruya, K., Kikuchi, Y., Yoshino, M., Kuwahara, T., Shirasaka, T., Kimura, S. and Oka, S.: Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun., 319: 1322-1326 (2004).
19. Mushiroda, T., Ohnishi, Y., Saito, S., Takahashi, A., Kikuchi, Y., Saito, S., Shimomura, H., Wanibuchi, Y., Suzuki, T., Kamatani, N. and Nakamura, Y.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet., 51: 249-253 (2006).